Genetic Analysis AS
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more
Genetic Analysis AS (GEAN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.182x
Based on the latest financial reports, Genetic Analysis AS (GEAN) has a cash flow conversion efficiency ratio of -0.182x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-5.37 Million) by net assets (Nkr29.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genetic Analysis AS - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Genetic Analysis AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genetic Analysis AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genetic Analysis AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Azincourt Uranium Inc
OTCQB:AZURF
|
-0.089x |
|
WD-40 CO (WD1.SG)
STU:WD1
|
0.118x |
|
Shrenik Limited
NSE:SHRENIK
|
0.003x |
|
JE Cleantech Holdings Ltd
NASDAQ:JCSE
|
0.001x |
|
Fiddlehead Resources Corp.
V:FHR
|
N/A |
|
Hansol Chemical Co. Ltd.
KQ:014680
|
N/A |
|
Hall of Fame Resort Entertainment Co
NASDAQ:HOFV
|
-0.053x |
|
CAPELLI NOM. EO 684
F:CP0
|
N/A |
Annual Cash Flow Conversion Efficiency for Genetic Analysis AS (2020–2024)
The table below shows the annual cash flow conversion efficiency of Genetic Analysis AS from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr22.49 Million | Nkr-8.50 Million | -0.378x | +29.86% |
| 2023-12-31 | Nkr32.00 Million | Nkr-17.23 Million | -0.539x | -22.17% |
| 2022-12-31 | Nkr44.14 Million | Nkr-19.46 Million | -0.441x | -15.07% |
| 2021-12-31 | Nkr72.09 Million | Nkr-27.62 Million | -0.383x | -172.44% |
| 2020-12-31 | Nkr46.62 Million | Nkr-6.56 Million | -0.141x | -- |